Table 1 Information on datasets

From: The genetic relationship between cannabis use disorder, cannabis use and psychiatric disorders

 

Phenotype

Type of phenotype

Effective sample size

Year of publication

PubMed ID (ref)

Cannabis traits

CanUD-EUR

Case–control

161,053

2023

3798582219

CanUD-AFR

Case–control

64,460

2023

3798582219

Cannabis use

Case–control

122,438

2018

3015066323

Psychiatric traits

Anxiety symptoms

Continuous

175,163

2020

3190670843

MDD

Case–control

709,980

2021

3404574432

SCZ

Case–control

58,749

2022

3539658030

BPD

Case–control

101,963

2021

3400209631

AN

Case–control

46,322

2019

3130854544

ADHD

Case–control

128,214

2023

3670299745

PTSD and subtypes

PCL–total

Continuous

186,689

2021

3351047647

PCL–avoidance

Continuous

186,689

2021

3351047647

PCL–hyperarousal

Continuous

186,689

2021

3351047647

PCL–reexperiencing

Continuous

186,689

2021

3351047647

Big Five personality traits

Neuroticism

Continuous

682,688

2024

3829313748

Extraversion

Continuous

298,772

2024

3829313748

Agreeableness

Continuous

252,749

2024

3829313748

Conscientiousness

Continuous

252,253

2024

3829313748

Openness

Continuous

237,390

2024

3829313748

  1. For the case–control studies, the given sample size represents the effective sample size. For CanUD and cannabis use, effective sample size was calculated as 4/(1/cases + 1/controls). For SCZ, BPD and AN, effective sample size was provided directly in the available summary statistics. For cannabis use and MDD, the available summary statistics excluded 23andMe data. SNP-heritability values are shown in Supplementary Table 1.